Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG-556

Experimental Neurology

Volumn 154, Issue 2, 1998, Pages 489-498

  Brenner, Talma ^a   Poradosu, Enrique ^b   Soffer, Dov ^a   Sicsic, Camille ^a   Gazit, Aviv ^b   Levitzki, Alexander ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Experimental autoimmune encephalomyelitis; Multiple sclerosis; Nitric oxide; Tumor necrosis factor ; Tyrphostins

Indexed keywords

5 (2,2 DICYANOVINYL) 2 NITROPHENOL; AG 1288; LIPOPOLYSACCHARIDE; N (4 BUTYLPHENYL) ALPHA CYANOCAFFEIC ACID AMIDE; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TYRPHOSTIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; HISTOPATHOLOGY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0032424332     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6971     Document Type: Article

References (50)

1. Adamson P., Tighe M., Pearson J. Protein tyrosine kinase inhibitors act downstream of IL-1 alpha and LPS stimulated MAP-kinase phosphorylation to inhibit expression of E-selection on human umbilical vain endothelial cells. Cell Adhes. Commun. 3:1996;511-525.
2. Benveniste E. N., Sparacio S. M., Betlog J. R. Tumor necrosis factor a enhances interferon-γ mediated class II antigen expression on astrocytes. J. Neuroimmunol. 25:1989;209-219.
3. Beutler B., Cerami A. Tumor necrosis, cathexia, shock and inflammation. Annu. Rev. Biochem. 57:1988;505-508.
4. Bo L., Dawson T. M., Wesselingh S., Mork S., Choi S., Kong P. A., Hanley D., Trapp B. D. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol. 36:1994;778-786.
5. Brenner T., Yamin A., Gallily R. Mycoplasma triggering of nitric oxide production by central nervous system glial cells and its inhibition by glucocorticoids. Brain Res. 641:1994;51-56.
6. Brenner T., Brocke S., Szafer F., Sobel R., Parkinson J. F., Perez D., Steinmann L. Inhibition of Nitric Oxide Synthase for treatment of Experimental Autoimmune Encephalomyelitis. J. Immunol. 158:1997;2940-2946.
7. Brenner T., Lisak R. P., Rostami A., Pleasure D. E., Silberberg D. H. Astrocytes oligodendrocytes and schwann cells share a common antigenic determinant that cross-reacts with myelin basic protein: identification with monoclonal antibody. J. Neurosci. 6:1986;1925-1933.
8. Chung I. Y., Benveniste E. N. Tumor necrosis factor α production by astrocytes, induction by lipopolysaccharide, INFα and IL-Iβ J. Immunol. 144:1990;2999-3007.
9. Corbett J. A., Kwon G., Marino M., Rodi C. P., Sullivan P., Turk J., McDaniel L. Tyrosine kinase inhibitors prevent cytokine-induced expression of iNOS and COX-2 by human islets. Am. J. Physiol. 270:1996;1581-1587.
10. Cross A. H., Cannella B., Brosnan C. F., Raine C. S. Homing to central nervous system vasculature by antigen-specific lymphocytes. Lab. Invest. 63:1990;162-170.
11. Feinstein D. L., Galea E., Cermak J., Chugh P., Lyndvert L., Reis D. J. Nitric oxide synthetase expression in glial cells. J. Neurochem. 68:1994;811-814.
12. Fontana A., Frei K., Bodmer S., Hofer E. Immune-mediated encephalomyelitis: On the role of antigen presenting cells in brain tissue. Immunol. Rev. 100:1987;185-201.
13. Frei K., Eyster H. P., Bopst H., Constantinescu C. S., Lavi E., Fontana A. Tumor Necrosis Factor-α and lymphotoxin a encephalomyelitis. J. Exp. Med. 12:1997;2177-2182.
14. Gazit A., Yaish P., Gilon C., Levitzki A. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 32:1989;2344-2352.
15. Gazit A., Osherov N., Posner I., Yaish P., Poradosu E., Gilon C., Levitzki A. Tyrphostins II: Heterocyclic and α-substituted Benzonemaloronitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine kinases. J. Med. Chem. 34:1991;1897-1907.
16. Hibbs J. B., Tantor R., Vaverin Z. Macrophage cytotoxicity; role for l-arginine deaminase and imino nitrogen oxidation to nitrite. Science. 235:1987;473-476.
17. Hickey W. F., Cohen J. A., Burns J. B. A quantitative immunohistochemical comparison of active versus adoptive induced experimental allergic encephalomyelitis in the Lewis rat. Cell. Immunol. 109:1987;272-282.
18. Hofman F. M., Hinton D. R., Johnson K., Merrill J. E. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170:1989;607-612.
19. Ji L., Zhang G., Hirabayashi Y. Inhibition of tumor necrosis factor alpha and ceramide-induced internucleosomal DNA fragmentation by herbimycin A in U937 cells. Biochem. Bisophys. Res. Commun. 212:1995a;640-647.
20. Ji L., Zhang G., Hirabayashi Y. Tumor necrosis factor alpha increases tyrosine phosphorylation of a 23-kDa nuclear protein in U937 cells through ceramide signaling pathway. Biochem. Biophys. Res. Commun. 215:1995b;489-496.
21. Kelly S. A., Goldshmidt-Clemont P. J., Millike E. E., Arai T., Smith E. H., Bulkey G. B. Protein tyrosine phosphorylation mediates TNF-induced endothelial-neutrophil adhesion in vitro. Am. J. Physiol. 274:1998;H513-H519.
22. Lee S. C., Liu W., Roth P., Dickson D. W., Berman J. W., Brosnan C. F. Macrophage colony stimulating factor in human fetal astrocytes and microglia: Differential regulation by cytokines and lipopolysaccharide, and modulation of class II MHC on microglia. J. Immunol. 150:1993;594-604.
23. Liberman A., Pitha P. H., Shin H. S., Shin H. L. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with Lipopolysaccharide or a neurotropic virus. Proc. Natl. Acad. Sci. USA. 86:1989;6348-6352.
24. Lopez-Talavera J. C., Levitzki A., Martinez M., Gazit A., Esteban R., Guardian J. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascots. J. Clin. Invest. 100:1997;664-670.
25. Martin D., Near S. L., Bendele A., Russel D. A. Inhibition of TNFα is protective against neurologic dysfunction after active immunization of Lewis rats with myelin basic protein. Exp. Neurol. 131:1995;221-228.
26. Martin R., McFarland H. F., McFarlin D. E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:1992;153-187.
27. Merrill J. E., Benveniste E. N. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci. 19:1996;331-338.
28. Merrill J. E., Ignarro L. J., Sherman M. P., Melniek J., Lane T. E. Microglia cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151:1993;2132-2141.
29. Minamide L. S., Bomberg J. R. A filter paper dye-binding assay for quantitative determination of protein without interdependence from reducing agents or detergents. Anal. Biochem. 190:1990;66-70.
30. Mishra S., Mathur R., Hamburger A. W. Modulation of the cytoxic activity of tumor necrosis factor by protein tyrosine kinase and protein tyrosine phosphatase inhibitors. Lyphokine Cytokine Res. 13:1994;77-83.
31. Novogrodsky A., Vanichkin A., Patya M., Gazit A., Osherov N., Levitzki A. Prevention of LPS-induced lethal toxicity by tyrosine kinase blockers. Science. 264:1994;1319-1322.
32. Raine C. S., Lee S. C., Scheinberg L. C., Dujvestijn A. M., Cross A. H. Adhesion molecules on endothelial cells in the central nervous system: An emerging area in the neuroimmunology of multiple sclerosis. Clin. Immunol. Immunopathol. 57:1990;173-187.
33. Raine C. S. Biology of disease analysis of autoimmune demyelination items impact upon multiple sclerosis. Lab. Invest. 50:1984;608-635.
34. Ruddle N. H., Bergman C. M., McGrath K. M., Lingenheld E. G., Grunnet M. L., Padula S. J., Clark R. B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1990;1193-1200.
35. Selmaj K., Raine C. S. Tumor necrosis factor mediates myelin and oligodendrocyte damagein vitro. Ann. Neurol. 23:1988;339-346.
36. Selmaj K. W., Farooq M., Norton W. T., Raine C. S., Brosnan C. F. Proliferation of astrocytesin vitro. J. Immunol. 144:1990;129-135.
37. Selmaj K., Raine C. S., Cross A. H. Anti-TNF therapy changes autoimmune demyelination. Ann. Neurol. 30:1991a;694-700.
38. Selmaj K., Raine C. S., Farooq M., Norton W. T., Brosnan C. F. Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J. Immunol. 157:1991b;1522-1529.
39. Selmaj K., Papierz W., Glabinski A., Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor. J. Neuroimmunol. 56:1995;135-141.
40. Sevransky J. E., Shaked G., Novogrodsky A., Levitzki A., Gazit A., Hoffman A., Elin R. J., Quezado Z. M., Freeman B. D., Eichacker P. Q. Tyrphostin AG-556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis. J. Clin. Invest. 15:1997;1966-1973.
41. Sharief M. K., Phil M., Hentges R. Association between TNFα and disease progression in patients with multiple sclerosis. N. En. J. Med. 325:1991;467-472.
42. Shohami E., Bass R., Wallach D., Yamin A., Gallily R. Inhibition of Tumor necrosis factor α activation in rat brain is associated with cerebroprotection after closed head injury. J. Cerebral Blood Flow Metab. 16:1996;378-384.
43. Stefanova I., Corcoran M. L., Horak E. M., Wahl L. M., Bolen J. B., Horak I. D. Lipopolysaccharide-induced activation of CD14-associated proteintyrosine kinase/p53/p56lyn. J. Biol. Chem. 268:1996;20725-20728.
44. Steinman L. A. Coordinated immunological attack against myelin in the central nervous system. Cell. 85:1996;299-302.
45. Steiman L. A. Some misconceptions about understanding autoimmunity through experiments with knockouts. J. Exp. Med. 12:1998;2039-2041.
46. Teuscher C., Hickey W. F., Korngold R. An analysis of the role of tumor necrosis factor in the phenotypic expression of actively induced experimental allergic orchitis and experimental allergic encephalomelitis. Clin. Immunol. Immunopathol. 54:1990;442-453.
47. Van Oosten B. W., Barkhof F., Truyen L., Boringa J. B., Bertelsmann F. W., Von Blomberg B. M. E., Woody J. N., Hartung H. P., Polman C. H. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 47:1996;1531-1534.
48. Vanichkin A., Patya M., Gazit A., Levitzki A., Novogrodsky A. Late administration of a Lipophilic Tyrosine kinase inhibitor Prevents Lipopolysacharide and Escherichia coli-Induced Lethal Toxicity. J. Infect. Dis. 173:1996;927-933.
49. Vassalli. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:1992;411-452.
50. Weber C., Negrescu E., Erl W., Pietsch A., Frankenberger M., Ziegler-Heitbrock H. W., Siess W., Weber P. C. Inhibitors of protein tyrosine kinase suppress TNF-stimulated induction of endothelial cell adhesion molecules. J. Immunol. 155:1995;445-451.